A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2 Article

Open Access

cited authors

  • Shaverdashvili, Khvaramze; Reyes, Vincent; Wang, Hong; Mehta, Dhaval; Marsh, Christopher; Waas, John K.; Vanderweele, Robert A.; Peracha, Sajid M.; Liang, Hongmei; Socinski, Mark A.; Gerber, David E.; Dowell, Jonathan E.; Villaruz, Liza C.

authors

Publication Date

  • December 15, 2023

webpage

published in

category

keywords

  • Durvalumab
  • Non-small cell lung cancer
  • Overall survival
  • Performance status 2
  • Safety

volume

  • 66